• Explore /
  • Poster
  • / Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.

Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy.

Abstract Poster

Authors

null

Benjamin Lerman

Children's Hospital of Philadelphia, Philadelphia, PA

Benjamin Lerman , Yimei Li , Meaghan Granger , Thomas Cash , Arhanti Sadanand , Katherine Somers , Aeesha Ranavaya , Michelle Choe , Jennifer Foster , Daniel A. Morgenstern , Margarida Simao Rafael , Keri A. Streby , Rachel Zeno , Rajen Mody , Sahr Yazdani , Ami Vijay Desai , Margaret E Macy , Suzanne Shusterman , Sara Michele Federico , Rochelle Bagatell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10025)

DOI

10.1200/JCO.2022.40.16_suppl.10025

Abstract #

10025

Poster Bd #

240

Abstract Disclosures

Similar Posters

First Author: Emily Gustava Greengard

First Author: Shakeel Modak

First Author: Godfrey Chi-Fung Chan

Poster

2020 ASCO Virtual Scientific Program

Outcome in patients with refractory high-risk neuroblastoma.

Outcome in patients with refractory high-risk neuroblastoma.

First Author: Amir Bari Siddiqui